CARDAMYST (Etripamil)

CARDAMYST (etripamil), from Milestone Pharmaceuticals, is the first self-administered nasal spray approved by the FDA to convert episodes of paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm in adults. It lets patients treat an episode wherever it happens instead of going to the emergency department.

Etripamil is a short-acting L-type calcium channel blocker that slows conduction through the AV node, interrupting the re-entry circuit behind PSVT. In the Phase 3 RAPID trial, 64% of patients returned to normal rhythm within 30 minutes versus 31% on placebo. One device (70 mg) is used at symptom onset; a second dose may be taken after 10 minutes if symptoms persist, up to 140 mg in 24 hours.

• Contraindicated in heart failure (NYHA class II–IV), WPW or other pre-excitation syndromes, sick sinus syndrome without a pacemaker, and second-degree (Mobitz II) or higher AV block.
• Fainting related to its effects on blood pressure and heart rate can occur; patients should seek emergency help if symptoms do not improve within 20 minutes of a second dose.
• Common side effects are nasal discomfort, congestion and runny nose.

What documents are required to import CARDAMYST to India?

CARDAMYST may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered cardiologist or electrophysiologist
• ECG documentation of PSVT
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription.

Is CARDAMYST available in India?

CARDAMYST was FDA-approved in December 2025 and is not available in India. It can be legally accessed through the Named Patient Program (NPP), subject to applicable regulations.

Indian Pharma Network (IPN) can source CARDAMYST from its authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For CARDAMYST cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: FDA-approved — 12 December 2025.
• European Union / Japan: Not approved as of October 2026.

What is CARDAMYST used for?

CARDAMYST (etripamil) is a fast-acting intranasal calcium channel blocker used for self-treatment of PSVT episodes.

Who manufactures CARDAMYST?

CARDAMYST is from Milestone Pharmaceuticals.

How does CARDAMYST work?

Etripamil is a short-acting L-type calcium channel blocker that slows conduction through the AV node, interrupting the re-entry circuit behind PSVT.

Can CARDAMYST be used at home?

Yes. It is designed for self-administration outside the hospital once a doctor has confirmed PSVT and prescribed it.

Is CARDAMYST approved by the US FDA?

Yes. The FDA approved CARDAMYST in December 2025.